{"id":792349,"date":"2026-02-24T16:44:02","date_gmt":"2026-02-24T16:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=792349"},"modified":"2026-02-24T16:44:02","modified_gmt":"2026-02-24T16:44:02","slug":"ct388-enters-phase-iii-in-2025-dual-glp1gip-candidate-targets-usd-150-billion-obesity-market-with-188-weight-loss-in-24-weeks-analyses-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/ct388-enters-phase-iii-in-2025-dual-glp1gip-candidate-targets-usd-150-billion-obesity-market-with-188-weight-loss-in-24-weeks-analyses-delveinsight_792349.html","title":{"rendered":"CT-388 Enters Phase III in 2025: Dual GLP-1\/GIP Candidate Targets USD 150 Billion Obesity Market with 18.8% Weight Loss in 24 Weeks, analyses DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1771962979.jpg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"CT-388 Enters Phase III in 2025: Dual GLP-1\/GIP Candidate Targets USD 150 Billion Obesity Market with 18.8% Weight Loss in 24 Weeks, analyses DelveInsight\" src=\"https:\/\/www.abnewswire.com\/upload\/2026\/02\/1771962979.jpg\" alt=\"CT-388 Enters Phase III in 2025: Dual GLP-1\/GIP Candidate Targets USD 150 Billion Obesity Market with 18.8% Weight Loss in 24 Weeks, analyses DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>CT-388 Sales Market<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">Basel, Switzerland \u2013 Swiss pharmaceutical leader Roche, through its subsidiary Genentech, is accelerating development of its investigational obesity and metabolic therapy CT-388, positioning the candidate as a potential next-generation competitor in the rapidly expanding global obesity and type 2 diabetes market.<\/div>\n<p style=\"text-align: justify;\">In <strong>September 2025<\/strong>, Roche advanced CT-388 into <strong>Phase III clinical development<\/strong>, marking a significant milestone in its strategy to compete with established incretin leaders such as <strong>Eli Lilly<\/strong> and <strong>Novo Nordisk<\/strong> in what analysts estimate could become a <strong>USD 150 billion annual market by the early 2030s<\/strong>.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Access the Complete CT-388 Sales Forecast Report (2034): Unlock detailed 7MM revenue projections, peak sales estimates, competitive benchmarking, and regulatory milestone analysis @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ct-388-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">CT-388 Sales Market Forecast<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CT-388 Drug Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">CT-388 is a <strong>once-weekly subcutaneous injectable dual GLP-1\/GIP receptor agonist<\/strong> designed for the treatment of <strong>obesity and type 2 diabetes mellitus (T2D)<\/strong>.<\/p>\n<p style=\"text-align: justify;\">The molecule was engineered with a distinctive <strong>biased signaling mechanism<\/strong>, demonstrating potent GLP-1 and GIP receptor activity with minimal &beta;-arrestin recruitment. This design aims to reduce receptor desensitization, prolong pharmacologic activity, enhance durability of effect, and potentially improve tolerability compared to traditional incretin therapies.<\/p>\n<p style=\"text-align: justify;\">CT-388 is currently in <strong>Phase II development<\/strong> for obesity (NCT06525935) and type 2 diabetes mellitus (NCT06628362).<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Discover how CT-388 compares to leading GLP-1\/GIP therapies from Eli Lilly and Novo Nordisk across efficacy, safety, pricing, and market positioning @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Factors Driving CT-388 Growth<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>1. Market Share Gains and Anticipated Patient Starts<\/strong><\/p>\n<p style=\"text-align: justify;\">CT-388 remains in clinical development and has not yet achieved commercial market share. However, early Phase Ib data suggest strong commercial potential upon approval.<\/p>\n<p style=\"text-align: justify;\">In <strong>May 2024<\/strong>, Genentech announced positive results from a 24-week Phase Ib trial in adults with obesity:<\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>18.8% mean placebo-adjusted weight loss (p &lt; 0.001)<\/strong><\/li>\n<li>100% achieved &gt;5% weight loss<\/li>\n<li>85% achieved &gt;10% weight loss<\/li>\n<li>70% achieved &gt;15% weight loss<\/li>\n<li>45% achieved &gt;20% weight loss<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">These results are clinically meaningful and compare favorably to other injectable GLP-1 or GLP-1\/GIP therapies at similar time points.<\/p>\n<p style=\"text-align: justify;\">Anticipated new patient starts will depend on Phase II\/III readouts and regulatory approvals. If efficacy and safety are maintained in larger populations and longer-duration trials, CT-388 could see rapid prescriber uptake.<\/p>\n<p style=\"text-align: justify;\">Roche is simultaneously scaling its obesity and metabolic portfolio following its Carmot Therapeutics acquisition, reinforcing long-term commercialization capabilities.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>2. Expansion Across Key Indications<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Obesity \/ Overweight (Primary Focus)<\/strong> CT-388 has demonstrated substantial weight loss in obese adult populations and is advancing into larger Phase II\/III trials.<\/p>\n<p style=\"text-align: justify;\"><strong>Type 2 Diabetes Mellitus (T2D)<\/strong> Additional study arms are evaluating CT-388 in patients with obesity and T2D. Early data indicate improvements in glucose homeostasis and normalization of glycemia in pre-diabetes subgroups.<\/p>\n<p style=\"text-align: justify;\">In Phase Ib, all treated participants with baseline pre-diabetes achieved glycemic normalization at Week 24 &mdash; an encouraging signal for metabolic disease prevention.<\/p>\n<p style=\"text-align: justify;\"><strong>Comorbid Cardiometabolic Risk Populations<\/strong> Ongoing studies include participants with pre-diabetes, hypertension, and dyslipidemia to assess whether CT-388 improves broader metabolic risk markers.<\/p>\n<p style=\"text-align: justify;\">Future Phase IIb and Phase III studies are expected to evaluate higher doses and longer treatment durations (72+ weeks), further clarifying durability, cardiometabolic impact, and safety profile.<\/p>\n<p style=\"text-align: justify;\"><strong><em> Discover how CT-388 compares to leading GLP-1\/GIP therapies from Eli Lilly and Novo Nordisk across efficacy, safety, pricing, and market positioning @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/ct-388-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/report-store\/ct-388-market-forecast<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>3. Geographic Expansion Strategy<\/strong><\/p>\n<p style=\"text-align: justify;\">CT-388 is being developed globally, with trials likely spanning North America, Europe, and other key regions.<\/p>\n<p style=\"text-align: justify;\">Following potential approvals, emerging markets such as Asia-Pacific and Latin America are expected to represent significant long-term growth opportunities, contingent on pricing and reimbursement alignment.<\/p>\n<p style=\"text-align: justify;\">Roche is scaling manufacturing capacity and expanding its metabolic disease infrastructure to support global commercialization.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Regulatory Status and Expectations<\/strong><\/p>\n<p style=\"text-align: justify;\">As of mid-2024:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Positive Phase Ib data completed<\/li>\n<li>Phase II \/ IIb trials underway<\/li>\n<li>Phase III trial initiated in 2025<\/li>\n<li>No regulatory approvals yet<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">Expected initial filings will likely target obesity first, followed by potential expansion into T2D and cardiometabolic risk populations.<\/p>\n<p style=\"text-align: justify;\">If approved in both obesity and diabetes, CT-388 would meaningfully diversify Roche&rsquo;s metabolic portfolio and establish a competitive presence in the incretin class.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Strong Volume Momentum Driven by Clinical Performance<\/strong><\/p>\n<p style=\"text-align: justify;\">The 24-week Phase Ib results highlight compelling weight-loss efficacy.<\/p>\n<p style=\"text-align: justify;\">Tolerability appears consistent with the incretin class, with primarily mild-to-moderate gastrointestinal side effects and no unexpected safety signals to date.<\/p>\n<p style=\"text-align: justify;\">This supports potential long-term adherence and real-world adoption, pending confirmation in larger datasets.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Gain quick insights into CT-388&rsquo;s Phase III progress, clinical differentiation, geographic expansion strategy, and projected growth drivers through 2034 @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Competitive Differentiation and Market Trends<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Dual GLP-1\/GIP Agonism + Biased Signaling<\/strong><\/p>\n<p style=\"text-align: justify;\">CT-388 differentiates itself via dual receptor targeting combined with minimized &beta;-arrestin recruitment.<\/p>\n<p style=\"text-align: justify;\">This may reduce receptor internalization and improve durability versus conventional incretin therapies.<\/p>\n<p style=\"text-align: justify;\"><strong>Efficacy Positioning<\/strong><\/p>\n<p style=\"text-align: justify;\">The 18.8% placebo-adjusted weight loss over 24 weeks positions CT-388 competitively within the obesity treatment landscape.<\/p>\n<p style=\"text-align: justify;\">If sustained or improved in longer trials, CT-388 could achieve best-in-class status.<\/p>\n<p style=\"text-align: justify;\"><strong>Safety and Tolerability<\/strong><\/p>\n<p style=\"text-align: justify;\">GI-related adverse events were mostly mild to moderate, consistent with the incretin class.<\/p>\n<p style=\"text-align: justify;\">No major safety signals emerged in early studies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Market Tailwinds Supporting CT-388<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Growing global obesity prevalence<\/li>\n<li>Increasing payer focus on metabolic disease prevention<\/li>\n<li>Rising demand for durable weight-loss therapies<\/li>\n<li>Expansion of cardiometabolic risk treatment strategies<\/li>\n<li>Emphasis on real-world evidence and long-term safety<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Risks and Headwinds<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Need for long-term safety validation (72+ weeks)<\/li>\n<li>Pricing and reimbursement pressures<\/li>\n<li>Strong competition from established brands<\/li>\n<li>Manufacturing and supply chain scalability<\/li>\n<li>Injectable route may limit access in some regions<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong><em>Request free sample report for ongoing updates on CT-388 clinical milestones, regulatory developments, and emerging competition in the incretin landscape @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/ct-388-market-forecast<\/a><\/em><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>CT-388 Market Report Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">The &ldquo;CT-388 Sales Forecast and Market Size Analysis &ndash; 2034&rdquo; report provides detailed insights across the 7MM:<\/p>\n<ul style=\"text-align: justify;\">\n<li>United States<\/li>\n<li>Germany<\/li>\n<li>France<\/li>\n<li>Italy<\/li>\n<li>Spain<\/li>\n<li>United Kingdom<\/li>\n<li>Japan<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The report covers:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Mechanism of Action (MoA)<\/li>\n<li>Dosage and administration<\/li>\n<li>Clinical development timeline<\/li>\n<li>Regulatory milestones<\/li>\n<li>Sales forecasts through 2034<\/li>\n<li>SWOT analysis<\/li>\n<li>Competitive intelligence<\/li>\n<li>Pricing and reimbursement insights<\/li>\n<li>Peak sales projections<\/li>\n<li>Pipeline competitor landscape<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Analytical Perspective<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s assessment evaluates CT-388&rsquo;s positioning relative to other emerging and marketed obesity\/T2D therapies, analyzing strengths, weaknesses, commercial potential, and anticipated uptake.<\/p>\n<p style=\"text-align: justify;\">The forecast incorporates:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Clinical data interpretation<\/li>\n<li>Market access assumptions<\/li>\n<li>Competitive landscape modeling<\/li>\n<li>Regional reimbursement dynamics<\/li>\n<li>Patent and generic entry considerations<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Outlook Through 2034<\/strong><\/p>\n<p style=\"text-align: justify;\">The CT-388 market scenario is expected to evolve significantly over the next decade.<\/p>\n<p style=\"text-align: justify;\">Strong clinical efficacy, differentiated receptor signaling, expansion into T2D and cardiometabolic populations, and Roche&rsquo;s global commercialization strategy position CT-388 as a potentially disruptive entrant in the metabolic disease landscape.<\/p>\n<p style=\"text-align: justify;\">If Phase III trials confirm early findings, CT-388 could emerge as a major contender in the global obesity and diabetes therapeutics market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56434.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=ct388-enters-phase-iii-in-2025-dual-glp1gip-candidate-targets-usd-150-billion-obesity-market-with-188-weight-loss-in-24-weeks-analyses-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +14699457679<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=ct388-enters-phase-iii-in-2025-dual-glp1gip-candidate-targets-usd-150-billion-obesity-market-with-188-weight-loss-in-24-weeks-analyses-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>CT-388 Sales Market Basel, Switzerland \u2013 Swiss pharmaceutical leader Roche, through its subsidiary Genentech, is accelerating development of its investigational obesity and metabolic therapy CT-388, positioning the candidate as a potential next-generation competitor in the rapidly expanding global obesity and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/ct388-enters-phase-iii-in-2025-dual-glp1gip-candidate-targets-usd-150-billion-obesity-market-with-188-weight-loss-in-24-weeks-analyses-delveinsight_792349.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,413],"tags":[],"class_list":["post-792349","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/792349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=792349"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/792349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=792349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=792349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=792349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}